Treatment Effects of Pulmonary Artery Denervation for Pulmonary Arterial Hypertension Stratified by REVEAL Risk Score: Results from PADN-CFDA Trial.
Juan ZhangJing KanYongyue WeiCaojin ZhangZhenwen YangHeping GuFenling FanHong GuQiguang WangDujiang XieGangcheng ZhangXiaomei GuoYuehui YinBowen JinHongmei ZhouZiyang YangZhouming WangYu XinChen ZhangLili MengXiaoyu WangChunxia ZhaoHang ZhangXiaoyan YanFeng ChenCheng YaoRaymond L BenzaGregg W StoneShao-Liang ChenPublished in: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2023)
In patients with PAH, PADN plus PDE-5i improved exercise capacity, NT-proBNP, hemodynamic, and clinical outcomes during the 6-month follow-up among intermediate-high risk patients.
Keyphrases
- pulmonary arterial hypertension
- pulmonary artery
- pulmonary hypertension
- coronary artery
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- clinical trial
- physical activity
- prognostic factors
- gene expression
- polycyclic aromatic hydrocarbons
- peritoneal dialysis
- smoking cessation
- resistance training